%20(3).png)
Flxion Medical (FM) is on a mission to transform the delivery of emergency medications. FM will achieve this by bringing to market the InFlx™ and the InFlx II Injectors, easy-to-use, compact, versatile, and reliable safety injectors that are both unique in design and affordable to everyone.
One American dies of drug overdose "nearly every five minutes around the clock-that's unacceptable" according to Rahul Gupta, MD, MPH, former Leader of the White House Office of National Drug Control Policy.
​
​
Flxion Medical Announces Groundbreaking Patent-Pending Injector Technology
​
We are proud to announce that Flxion Medical has officially filed a new patent application with the United States Patent and Trademark Office (USPTO) for a proprietary injector that represents a major advancement in emergency medication delivery. This new device has been redesigned to be more intuitive, ergonomically optimized, and versatile—providing greater flexibility in time-critical scenarios where every second counts.
Revolutionizing Emergency Care
Today successful intervention during an opioid overdose or an anaphylactic reaction—both of which can be fatal—depends on the rapid administration of medications such as Naloxone or Epinephrine. These drugs are typically delivered through one of three routes: intranasal (IN), intramuscular (IM), or intravenous (IV).But what happens when intranasal administration fails due to blocked nasal passages? In such cases, the only life-saving option is intramuscular injection—and if that’s not readily available, the outcome can be tragic. Our new InFlx™ Injector addresses this critical need with an unprecedented, patent-pending design: a single, low-cost device capable of delivering medications via IN, IM, or IV routes—a breakthrough unmatched by any other product on the market.
A New Standard for Life-Saving Technology
This innovative, adaptable delivery system is designed to render current single-route injectors obsolete. Whether for opioid reversal or anaphylaxis treatment, our universal injector is engineered for both professional responders and lay users, ensuring swift, reliable intervention under the most life threatening situations.
​
Once the patent is granted for this new provisional patent filing technology, we will publicly announce it on our website.
Our Patented Technology
Affordable Life Saving Technology
Due to its unique design, there is no competitor in today’s market with the versatility of the InFlx™ Injector, nor will there be until 2037. InFlx's patented technology provides critical advantages over all competitors when a matter of seconds can mean the difference between life and death. This is accomplished using the same injector for Intramuscular, Intranasal, intravenous, and Intraosseous. No other injector on the market today has the capability of converting the same injector for all four applications in a simple low-cost device.
FM has also developed the InFlx II Injector, an innovative one-handed dual-chamber injector with a safety shielded needle that can deliver biologics. One chamber of medicament is provided in a lyophilized form and is mixed with a diluent prior to injection to reconstitute the medicament. Storage in the lyophilized form increases the shelf life and efficacy of the medicament in situations such as in third world countries where refrigeration may not be available.
FM's focus is on the development and manufacturing of a low-cost drug injectable for the civilian emergency market of Epinephrine and Naloxone in the United States and worldwide. FM will then sell these same generic drugs housed in our injector, for the worldwide NATO and civilian emergency medicine markets. Lastly, FM will deliver proprietary pharmaceuticals utilizing our low-cost injectors to the Pharma, Biotech, and Vaccine markets through partnerships.
​​
Technology Demo
The Flxion Medical Team
James M. Donegan
Co-Founder/Chairman/CEO
James (Jim) M. Donegan is Co-Founder, Chaiman and Chief Executive Officer of Flxion Medical. FM's focus is on the development and manufacturing of a low-cost drug injectable for the civilian emergency market of Epinephrine and Naloxone in the United States and worldwide.
Previously, Jim was a co-founder, Principal and the CEO of the Meta Energy Group, LLC and the Oil Meta Trust, sponsored by the Meta Energy Group. He was the founder, CEO and President of the JMD Financial Consultant Group, where he provided consultant services in energy and fuel cost. Prior to his consultant services, Jim was a co-founder, chairman, CEO and president of the Med-Design Corporation, a publicly traded company from 1995 to 2005. The company invented, developed and manufactured safety medical devices. Through his contacts and resources, Jim successfully facilitated the mandate of the Needlestick Safety and Prevention Act (NSPA) signed by President Bill Clinton. Before Med Design, Jim was the Vice-President and Director of Marketing of Chase Manhattan Bank, NA, Structured Investment Products Division and Managing Director of Chase Manhattan Futures Corporation. Prior to Chase, Jim was Senior Vice President of Kidder Peabody and Company, West Coast Division, where he managed the marketing and trading of all financial futures products.
The following is Security Exchange active licensing held by Jim: Series 3, Commodities (NCFE), Series 4, Registered Option Principal (ROP), Series 7, Securities (FINRA), Series 63, State Registration (Blue Sky Laws).
Jim was a finalist for Entrepreneur of the Year 1998, an award sponsored by the Philadelphia Business Association. In 1993, he was an Excalibur nominee, an award in finance given by Chase Manhattan Bank. He also lectured at the University of Southern California to the MBA graduating classes for two consecutive years on futures and derivatives trading strategies such as portfolio insurance and stock index arbitrage.
Thor R. Halseth
Founder/CTO
Thor R. Halseth is the Founder, Chief Technology Officer and the inventor of the Flxion Medical Technology. Since graduating from both Montana State University and then Art Center College of Design as an Industrial designer, Thor has been granted inventor or co-inventor of record for 52 safety-needle patents, 63 overall patents and 35 pending patents.
​
Early in his career, Thor worked for Designworks USA, a prestigious consulting design firm in Southern California. He then Co-Founded the Med-Design Corporation which was taken public on the Nasdaq stock exchange and in turn licensed nine of its safety-needle patents to Becton Dickinson. After Thor left Med-Design to start Now Medical, his patented designs became the US market leader in Safety Huber Needles before it was sold to C.R.Bard. He then formed and sold Aduro Display where he conceived, designed and manufactured a low-voltage LED lighted shelving system for the retail market. Before forming Flxion Medical, Thor co-founded Action Medical Technologies where he designed and was issued patents for the Inflx™ and Inflx II injectors. He is now developing the Inflx and Inflx II injectors through Flxion Medical.
​
Thor's designs have been awarded the IDSA Idea Award, the Good Design Award from the Chicago Athenaeum Museum of Architecture and Design and the Best of Global Shop Gold award.
Click below to view the current medical devices on the market from Thor's patented designs:
​
Huber Plus Safety Infusion Set
BD Integra™ Retracting Syringe
​
BD Vacutainer® Push-Button Blood Collection Set
“For over 30 years, I have devoted myself to the invention and development of safety needle products for the protection and prevention of life-threatening diseases. I have now invented the proprietary low-cost InFlx™ and the InFlx II injectors not only to save lives but also to be an affordable alternative to the autoinjectors offered today.”
Get in Touch
For More Information or Investment Opportunity
Flxion Medical